Calls

  • Autonomous Drive Ambition Cities (IA) – Apply AI

    Opened

    Code: 41477 | Identifier Code: HORIZON-BRIDGING-2027-01-10 | Programme name: 2939 | Start submission calls: 20/10/2026 | End submission calls: 16/02/2027

    Support cities or urban agglomerations (from countries who have signed or plan to sign the “Joint Declaration of Intent concerning the creation of a cross-border testbed for the deployment of autonomous vehicles” or can demonstrate a comparable level of technological, operational and regulatory readiness) partnering with mobility service provider(s) and operator(s), vehicle manufacturers and suppliers, technology providers, R&I entities and public transport operators (as needed and appropriate), to deploy AI-enabled electric autonomous vehicles, with automation capabilities at level 4 (SAE), to enable autonomous driving operations, such as autonomous shuttle services, ride-hailing, car sharing and autonomous point to point navigation. Facilitate the sharing of knowledge, best practices, and recommendations among participating cities, industry, and with wider EU stakeholders.

  • EU AI Media Platform – modular multilingual public-interest infrastructure for European news and audiovisual media (IA) – Apply AI

    Opened

    Code: 41474 | Identifier Code: HORIZON-BRIDGING-2027-01-09 | Programme name: 2939 | Start submission calls: 20/10/2026 | End submission calls: 16/02/2027

    This topic will support pilots for AI-enabled media infrastructures, fostering research and innovation in the European media sector.

    It should deliver innovative solutions by consolidating, integrating and validating reusable AI-enabled infrastructure components and governance arrangements of platform pilots for pan-European public-interest media platform(s), making use, where appropriate, of European AI infrastructure and building on results from relevant Horizon Europe, Digital Europe and pilot actions, in preparation for wider scale-up from 2028 onward.

  • Call for Proposals ΥΕ_ΔΑ_ΤΑΜΕ_01_2026

    Opened

    Code: 41471 | Identifier Code: ΥΕ/ΔΑ/ΤΑΜΕ/01_2026 | Programme name: 31113 | Sub-program: AMIF Asylum, Migration and Integration Fund / Co-Financed | Start submission calls: 30/10/2026 | End submission calls: 18/12/2026

    The Directorate of European Funds of the Ministry of the Interior, as the Managing Authority for the Home Affairs Funds for the 2021–2027 programming period, has launched a Call for Proposals under reference ΥΕ/ΔΑ/ΤΑΜΕ/01_2026, within the framework of the Asylum, Migration and Integration Fund Programme and in accordance with the objectives set out in Article 3 of Regulation (EU) 2021/1147 of the European Parliament and of the Council of 7 July 2021 establishing the Asylum, Migration and Integration Fund.

  • Call for proposals for action grants to support transnational projects on judicial training covering civil law, criminal law or fundamental rights (2026)

    Opened

    Code: 41468 | Identifier Code: JUST-2027-JTRA | Programme name: 2915 | Start submission calls: 28/10/2026 | End submission calls: 04/03/2027

    Each project should include training activities that are tailored to the daily professional needs or identified challenges in the application of EU law23 and should be practical, interactive, and accessible to all learners, including practitioners with disabilities, irrespective of the format(s) of the activities: face-to-face, blended, hybrid or online format.

    The gender equality perspective should be considered when designing the ‘format’ of the training activities and gender balanced participation in training activities must be promoted and ensured. Moreover, a gender-sensitive approach should be taken for the identification of good practices, data collection (including sex-disaggregated statistics) and information dissemination.

  • Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases

    Opened

    Code: 41464 | Identifier Code: HORIZON-HLTH-2027-02-TOOL-01-two-stage | Programme name: 2939 | Sub-program: Health (Cluster 1) (2021-2027) | Start submission calls: 29/10/2026 | End submission calls: 17/02/2027

    Biomarkers are invaluable tools for improving patient outcomes, guiding treatment decisions, accelerating personalised medicine, more effective clinical research and the development of better medicines.

    However, despite the scientific discoveries of many clinically relevant biomarkers, estimated on the scale of tens of thousands, only a few biomarkers have been implemented in clinical practice. The traditional ‘one biomarker’ paradigm is insufficient for addressing the unmet clinical needs of chronic, progressive and multifactorial diseases, due to the complexity of the clinical phenotypes characterised by broad inter-and intra-patient heterogeneity. The established biomarkers have limitations in their use as prognostic and predictive indicators, for the assessment of the disease progression and the choices of the optimal therapeutic interventions tailored to the patients’ characteristics.

    Therefore, the topic focuses on the clinical development of predictive biomarkers of disease progression and treatment response for chronic non-communicable diseases (excluding cancer) by using established AI methodologies able to combine data of clinically used and candidate biomarkers, with available data from relevant clinical studies, longitudinal and Real-World Data (RWD). This topic is expected to support collaborative projects paving the way for future innovations in personalised medicine and enabling more timely and effective therapeutic interventions.

  • Addressing disabilities through the life course to support independent living and inclusion

    Opened

    Code: 41461 | Identifier Code: HORIZON-HLTH-2027-01-STAYHLTH-01 | Programme name: 2939 | Sub-program: Health (Cluster 1) (2021-2027) | Start submission calls: 29/10/2026 | End submission calls: 17/02/2027

    The focus of this topic is human-centred on persons with long-term disabilities -physical, mental, intellectual or sensory- aiming at supporting independent living across the life-course from a health perspective. Persons with disabilities have an equal right to live independently and be included in the community. Independent living requires a differentiated landscape of quality, accessible, person-centred and affordable, community- and family-based services comprising personal assistance, medical and social care and interventions by social workers, thereby facilitating everyday activities and providing choice to persons with disabilities and their families.

    The objective of this topic is to explore new ways to promote independent living and inclusion in society of persons with disabilities, reducing to the maximum possible the impact of barriers faced in their daily lives, and supporting the transition from institutions to living in the community while addressing all-encompassing aspects of personal support, such as community transformation, service provision, assistive and accessible technologies and environments.

  • Portable and versatile Point-of-care diagnostics

    Opened

    Code: 41457 | Identifier Code: HORIZON-HLTH-2027-02-IND-02-two-stage | Programme name: 2939 | Sub-program: Health (Cluster 1) (2021-2027) | Start submission calls: 29/10/2026 | End submission calls: 17/02/2027

    Point-of-Care (PoC) medical testing has made great technical progress (e.g. improved extraction, microfluidics, miniaturisation, and data processing techniques) with PoC test accuracies nearly matching those of lab-based tests. PoC tests may thus be an alternative to laboratory testing methods, enabling faster diagnostic results and therapeutic decision making. However, PoC testing is not always achieving a completely accurate diagnosis and one of the major issues with PoC diagnostics is the occurrence of false results during testing, another one is the often-cumbersome sample preparation. Hence there is a need for PoC diagnostics that are more sensitive, selective and easy-to-use allowing for improved clinical practice.

  • Development of cell-free protein synthesis platforms for discovery and/or production of biologicals

    Opened

    Code: 41454 | Identifier Code: HORIZON-HLTH-2027-01-IND-01 | Programme name: 2939 | Sub-program: Health (Cluster 1) (2021-2027) | Start submission calls: 29/10/2026 | End submission calls: 17/02/2027

    Cell-Free Protein Synthesis (CFPS) has been employed in fundamental biological research for decades, however, interest for the approach as a viable means for drug development and production has only emerged in recent years. The advantages that CFPS provides in terms of efficiency, simplicity, flexibility, cost- and time savings outweigh the hurdles that are still to be overcome for CFPS to become a routine manufacturing system for peptide- or protein-based biologicals.

  • Tools and technologies to support health adaptation to climate change

    Opened

    Code: 41452 | Identifier Code: HORIZON-HLTH-2027-01-ENVHLTH-MISSCLIMA-03 | Programme name: 2939 | Sub-program: Health (Cluster 1) (2021-2027) | Start submission calls: 29/10/2026 | End submission calls: 17/02/2027

    Enhancing the adaptive capacity and resilience of healthcare systems and communities is crucial to prevent and reduce the health impacts of climate change. However, many of the urgently needed technologies, tools, systems and solutions are still at an early developmental stage, relying on further support for development and testing.

    Proposals under this topic are expected to close this gap and build on innovations being developed in the field, supported through, among others, EU Research and Innovation (R&I) funding. In this context, Pre-commercial Procurement (PCP) projects can drive innovation and speed up the development of technologies for health adaptation to climate change by supporting the research and development of solutions to increase the resilience and preparedness of healthcare systems, communities and individuals against climate change.

    By focusing on early-stage solutions, PCP fosters collaboration between public sector buyers (e.g. public authorities, local authorities, health organisations) and private developers to create climate adaptation technologies, systems and solutions in the context of human health.

    These solutions will accelerate the transition to more climate-resilient healthcare systems and societies.

  • Integrating climate-related exposures into the human exposome and characterising its changes in response to climate change

    Opened

    Code: 41449 | Identifier Code: HORIZON-HLTH-2027-01-ENVHLTH-02 | Programme name: 2939 | Sub-program: Health (Cluster 1) (2021-2027) | Start submission calls: 29/10/2026 | End submission calls: 17/02/2027

    The exposome is the totality of exposures (and their interactions) experienced by an individual throughout their lifetime, including chemical, physical, biological, nutritional and psychosocial factors, from conception onwards. Many of these factors originate in the environment, including climate-related exposures such as extreme heat, heightened air pollution or drought.

    Climate change may amplify or interact synergistically with other better-established exposures, dynamically altering the human exposome and its health implications. Despite this, climate factors remain underrepresented in large-scale human exposome studies.

  • Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications

    Opened

    Code: 41446 | Identifier Code: HORIZON-HLTH-2027-01-CARE-02 | Programme name: 2939 | Sub-program: Health (Cluster 1) (2021-2027) | Start submission calls: 29/10/2026 | End submission calls: 17/02/2027

    While medicinal products contribute considerably to the health of EU citizens, they can also have adverse reactions.

    It is estimated that around 5% of all hospital deaths are due to an adverse drug reaction. On average, 16% of hospitalised older patients experience significant ADRs, varying in severity and mostly preventable, with commonly prescribed drug classes (such as diuretics, anti-bacterials, antithrombotic agents, analgesics, antineoplastics, etc.) accounting for most ADRs.

    Overall, ADRs increase morbidity, mortality, hospitalisations, and healthcare costs.

  • Clinical trials for advancing innovative interventions for neurodegenerative diseases

    Opened

    Code: 41443 | Identifier Code: HORIZON-HLTH-2027-02-DISEASE-14-two-stage | Programme name: 2939 | Sub-program: Health (Cluster 1) (2021-2027) | Start submission calls: 29/10/2026 | End submission calls: 17/02/2027

    Neurodegenerative diseases are a high burden for patients, caregivers, health systems and society. Given the limitations with current therapeutic solutions, including that they primarily address symptoms rather than underlying causes and can have serious side effects, together with the increasing prevalence of neurodegenerative diseases in an aging population, there is a huge need to develop more innovative, safer and more effective therapeutic solutions for these diseases.

    To further enhance their safety and effectiveness, the therapeutic solution based on an active substance should be combined/complemented with another multidisciplinary approach (e.g. lifestyle changes, cognitive training, rehabilitation therapies).

    Together this innovative intervention should lead to an improved quality of life and reduce the societal impact of these diseases.